Acute myeloid leukemia miRNA and transcription factor system and its construction method and application

Abstract

The invention relates to an acute myeloid leukemia miRNA and transcription factor model and a construction method and application thereof. The construction method includes: acquiring differential expression miRNA and different expression transcription factors of marrow samples of acute myeloid leukemia patients and a healthy contrast group, constructing a miRNA-transcription factor regulatory network model to obtain core miRNA and core transcription factors, and the like. The constructed miRNA and transcription factor model can be used for construction of diagnosis probes, chips or reagents, equipment and the like to provide intermediate result information or reference information for diagnosis of the acute myeloid leukemia patients. By the acute myeloid leukemia miRNA and transcription factor model, microRNA mediated network regulation contents are enriched, and an action mechanism of a microRNA and transcription factor mediated regulation network in AML (acute myeloid leukemia) is revealed. Research results lay the foundation for development of anti-leukemia medicines or biological products, and high application value is achieved.

Description

technical field [0001] The invention relates to the field of disease research, in particular to a miRNA and transcription factor model of acute myeloid leukemia and its construction method and application. Background technique [0002] Acute myeloid leukemia (AML) is a type of clonal proliferative acute hematologic malignancy derived from myeloid hematopoietic stem / progenitor cells, and it occurs frequently in middle-aged and elderly people. Elderly patients over 65 years old account for about 54% of AML. Different from the local invasive growth of solid tumors, AML is easy to spread throughout the body, invading various organs and tissues and causing fatal infection and hemorrhage. . The long-term survival rate of AML patients under 60 years old is 30% to 40%, and the long-term survival rate of patients over 60 years old is only 10%. The average survival period of untreated patients is only about 3 months, and the prognosis is poor. . AML seriously endangers human healt...

AI Technical Summary

Problems solved by technology

The long-term survival rate of AML patients under 60 years old is 30% to 40%, and the long-term survival rate of patients over 60 years old is only 10%. The average survival period of untreated patients is only about 3 months, and the prognosis is poor.

However, for elderly AML patients, various methods including chemotherapy and autologous peripheral blood stem cell transplantation cannot improve the overall curative effect, and their prognosis has not improved significantly in the past 30 years, especially for patients over 65 years old within 1 or 2 years after diagnosis The mortality rates were 86%, 94%

Images